Takara Bio

Takara Bio OCF/Debt

Delisted

The Operating Cash Flow to Debt Ratio of Takara Bio (4974.T) as of Nov 19, 2026 is 530.79 %. In the previous year, Operating Cash Flow to Debt Ratio was 176.86 % — a change of 200.12% (higher).

OCF/Debt

530.79 %

YoY

200.12%

Last updated:

Operating Cash Flow to Debt Ratio of Takara Bio is 2025 530.79 % . Operating Cash Flow to Debt Ratio of Takara Bio was 2024 176.86 % . It decreases by 200.12% higher compared to the previous year.

The Takara Bio OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2016
1,557.22 JPY
Jan 1, 2017
2,778.29 JPY
Jan 1, 2020
565.89 JPY
Jan 1, 2021
1,221.82 JPY
Jan 1, 2022
667.14 JPY
Jan 1, 2023
3,795.88 JPY
Jan 1, 2024
176.86 JPY
Jan 1, 2025
530.79 JPY
The Takara Bio OCF/Debt history
YEAROCF/DebtYoY
530.79 %+200.12%
176.86 %-95.34%
3,795.88 %+468.98%
667.14 %-45.40%
1,221.82 %+115.91%
565.89 %-79.63%
2,778.29 %+78.41%
1,557.22 %+3.73%
1,501.27 %+142.55%
618.96 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Takara Bio Stock analysis

What does Takara Bio do? Takara Bio Inc is a Japanese biotechnology company that has been active in the medical and life science industry since its founding in 1967. The company is a strong player in the field of molecular biology and operates in several countries such as the USA, Europe, and Asia. Takara Bio Inc was established as an independent company in 1999, focusing exclusively on the production of molecular biology products. The company offers a wide range of products in the fields of research and diagnostics, including enzymes, PCR kits, vectors and plasmids, antibodies, proteins, and cell culture products. Takara Bio Inc is organized into two divisions: Life Science Research and Diagnostics. The Life Science Research division provides products and solutions for research and development in areas such as molecular biology, neuroscience, proteomics, and genomics. The Diagnostics division offers products and solutions for clinical diagnostics and drug development. Takara Bio Inc also specializes in the automation of molecular biology procedures and offers automated systems that can perform processes such as nucleic acid extraction, PCR, and sequencing. The company is committed to sustainability and environmental protection, adhering to strict environmental and quality standards in its production processes and implementing waste reduction and efficient resource utilization programs. Overall, Takara Bio Inc is a leading company in the field of molecular biology, offering a wide range of products and solutions for research and diagnostics, and has become a key player in the life science industry through its global expansion and ability to provide custom solutions. Takara Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Takara Bio stock

Operating Cash Flow to Debt Ratio of Takara Bio is 530.79 % in 2025.

Operating Cash Flow to Debt Ratio of Takara Bio changed from 176.86 % to 530.79 %, representing a 200.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Takara Bio since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Takara Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Takara Bio

All Key Metrics — Takara Bio